<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05107596</url>
  </required_header>
  <id_info>
    <org_study_id>201807140</org_study_id>
    <nct_id>NCT05107596</nct_id>
  </id_info>
  <brief_title>Evaluation of CCR2 in Patients Post Myocardial Infarction</brief_title>
  <official_title>Preliminary Evaluation of 64Cu-DOTA-ECL1i in Patients Post-ST-Elevation Myocardial Infarction(STEMI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the feasibility of 64Cu-DOTA-ECL1i, an investigational PET imaging drug, at the&#xD;
      cellular level in the myocardium for individuals who have suffered a heart attack or who have&#xD;
      other inflammatory heart disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the feasibility of 64Cu-DOTA-ECL1i to detect CCR2+monocytes and macrophages&#xD;
      which are cells that are responsible for protecting tissues from foreign substances in the&#xD;
      myocardium by PET/MR and PET/CT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2018</start_date>
  <completion_date type="Anticipated">November 24, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who have heart disease as shown in the images</measure>
    <time_frame>1 or 2 days</time_frame>
    <description>PET images will be reconstruction using an iterative algorithm that incorporates resolution recovery, and will be corrected for attenuation using their respective CT or MR data sets</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>Post ST Elevation Myocardial Infarction/ Heart Attack</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Image patients who have had a heart attack</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarcoidosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Image patients who have Sarcoidosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myocarditis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Image patients with Myocarditis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiomyopathy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Image patients with cardiomyopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infected Cardiovascular Implantable Electronic Devices</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Image patients with cardiovascular implanted medical devices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Image healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>64Cu-DOTA-ECL1i</intervention_name>
    <description>Inject PET Radioisotope for imaging</description>
    <arm_group_label>Cardiomyopathy</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Infected Cardiovascular Implantable Electronic Devices</arm_group_label>
    <arm_group_label>Myocarditis</arm_group_label>
    <arm_group_label>Post ST Elevation Myocardial Infarction/ Heart Attack</arm_group_label>
    <arm_group_label>Sarcoidosis</arm_group_label>
    <other_name>Imaging drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy Volunteers:&#xD;
&#xD;
          2. Age 21 to 80 years of either sex, any race&#xD;
&#xD;
          3. Capable of lying still and supine within the PET/CT and PET/MR scanner for 1 hour and&#xD;
             follow instructions for breathing protocol during the CT portion&#xD;
&#xD;
          4. No illicit drug use or other inhaled drug use (including pharmacologic agents,&#xD;
             recreational agents, or illicit drugs) within the past year&#xD;
&#xD;
          5. No known history of cardiac. pulmonary, hepatic, or renal disease or diabetes&#xD;
&#xD;
          6. No history of claustrophobia or other preventing condition that has previously or&#xD;
             would interfere with completion of protocol-specified imaging sessions&#xD;
&#xD;
          7. Able to comprehend and willing to follow instructions for the study procedures as&#xD;
             called for by the protocol.&#xD;
&#xD;
        Inflammatory Heart Disease&#xD;
&#xD;
          1. Age 21 to 80 years of either sex, any race who have suffered a STEMI within the past 6&#xD;
             months as well as other forms of inflammatory heart disease including sarcoidosis,&#xD;
             myocarditis, cardiomyopathy, injected cardiovascular implantable electronic devices&#xD;
             pacemakers/LVAD&#xD;
&#xD;
          2. Are clinically stable to undergo imaging with either PET/MR or PET/CT.&#xD;
&#xD;
          3. Capacity to give written informed consent and ability to follow study procedures&#xD;
&#xD;
          4. Pre-menopausal women must have a negative urine pregnancy test within 24 hours prior&#xD;
             to the administration of 64-Cu-DOTA-ECL1i.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Healthy volunteers:&#xD;
&#xD;
          1. Currently enrolled in another study using an investigational drug&#xD;
&#xD;
          2. Angina&#xD;
&#xD;
          3. Uncontrolled heart failure&#xD;
&#xD;
          4. uncontrolled hypertension baseline hypotension below 90/50&#xD;
&#xD;
          5. Has any condition that in the opinion of the PI or designee that could increase risk&#xD;
             to the subject&#xD;
&#xD;
          6. Is deemed likely to be unable to perform all research procedures&#xD;
&#xD;
          7. Have contraindications to PET/CT imaging like claustrophobia&#xD;
&#xD;
          8. Have contraindication to gadolinium&#xD;
&#xD;
          9. Pregnant or breastfeeding&#xD;
&#xD;
         10. Currently using recreational drubs&#xD;
&#xD;
         11. Body weight of more than 300 lbs&#xD;
&#xD;
         12. Active symptoms or history of cardiac, pulmonary, hepatic or renal disease or diabetes&#xD;
&#xD;
         13. currently taking any prescription medications&#xD;
&#xD;
         14. Presence of an implanted device incompatible with CT or MRI scanning Inflammatory&#xD;
             Heart Disease&#xD;
&#xD;
        1) Clinically unstable including post MI angina, uncontrolled heart failure, sever&#xD;
        hypertension, hypotension AV block 2) Has any condition that in the opinion of the PI could&#xD;
        increase risk to the subject 3) Claustrophobia 4) contraindication to gadolinium contrast&#xD;
        5) Pregnant 6) Currently using recreational drugs 7) Body Weight more than 300 lbs 8)&#xD;
        Currently enrolled in another study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kitty D Harrison, BSN, RN</last_name>
    <phone>314-747-0183</phone>
    <email>kittydharrison@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kitty Harrison</last_name>
      <phone>314-747-0183</phone>
      <email>harrisonk@mir.wustl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

